Literature DB >> 16480278

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.

Peter C Meltzer1, David Butler, Jeffrey R Deschamps, Bertha K Madras.   

Abstract

Dopamine, serotonin, and norepinephrine are essential for neurotransmission in the mammalian system. These three neurotransmitters have been the focus of considerable research because the modulation of their production and their interaction at monoamine receptors has profound effects upon a multitude of pharmacological outcomes. Our interest has focused on neurotransmitter reuptake mechanisms in a search for medications for cocaine abuse. Herein we describe the synthesis and biological evaluation of an array of 2-aminopentanophenones. This array has yielded selective inhibitors of the dopamine and norepinephrine transporters with little effect upon serotonin trafficking. A subset of compounds had no significant affinity at 5HT1A, 5HT1B, 5HT1C, D1, D2, or D3 receptors. The lead compound, racemic 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one 4a, was resolved into its enantiomers and the S isomer was found to be the most biologically active enantiomer. Among the most potent of these DAT/NET selective compounds are the 1-(3,4-dichlorophenyl)- (4u) and the 1-naphthyl- (4t) 2-pyrrolidin-1-yl-pentan-1-one analogues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480278      PMCID: PMC2602954          DOI: 10.1021/jm050797a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

Review 1.  2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.

Authors:  F Ivy Carroll
Journal:  J Med Chem       Date:  2003-05-08       Impact factor: 7.446

2.  Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate.

Authors:  Peter C Meltzer; Pinglang Wang; Paul Blundell; Bertha K Madras
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

3.  Synthesis of 6- and 7- hydroxy-8-azabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.

Authors:  P C Meltzer; B Wang; Z Chen; P Blundell; M Jayaraman; M D Gonzalez; C George; B K Madras
Journal:  J Med Chem       Date:  2001-08-02       Impact factor: 7.446

4.  Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance.

Authors:  A R Holliday; R B Morris; R P Sharpley
Journal:  Psychopharmacologia       Date:  1964-09-11

Review 5.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

Review 6.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Monoamine transporters: from genes to behavior.

Authors:  Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-09-17       Impact factor: 13.820

8.  Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes.

Authors:  F Ivy Carroll; Neil Pawlush; Michael J Kuhar; Gerald T Pollard; James L Howard
Journal:  J Med Chem       Date:  2004-01-15       Impact factor: 7.446

9.  Design and synthesis of an irreversible dopamine-sparing cocaine antagonist.

Authors:  Peter C Meltzer; Shanghao Liu; Heather Blanchette; Paul Blundell; Bertha K Madras
Journal:  Bioorg Med Chem       Date:  2002-11       Impact factor: 3.641

10.  Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors.

Authors:  Bertha K Madras; Michele A Fahey; Gregory M Miller; Richard De La Garza; Martin Goulet; Roger D Spealman; Peter C Meltzer; Susan R George; Brian F O'Dowd; Ali A Bonab; Eli Livni; Alan J Fischman
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

View more
  76 in total

1.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

2.  The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Authors:  Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

3.  Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Authors:  Amy J Eshleman; Shanthi Nagarajan; Katherine M Wolfrum; John F Reed; Tracy L Swanson; Aaron Nilsen; Aaron Janowsky
Journal:  Psychopharmacology (Berl)       Date:  2018-11-05       Impact factor: 4.530

4.  Chiral resolution and absolute configuration of the enantiomers of the psychoactive "designer drug" 3,4-methylenedioxypyrovalerone.

Authors:  Masaki Suzuki; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Chirality       Date:  2015-02-26       Impact factor: 2.437

5.  Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV).

Authors:  Brittany L Murray; Christine M Murphy; Michael C Beuhler
Journal:  J Med Toxicol       Date:  2012-03

6.  Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones.

Authors:  Michael B Gatch; Cynthia M Taylor; Michael J Forster
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

7.  Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery.

Authors:  David Nutt
Journal:  Ther Adv Psychopharmacol       Date:  2011-04

8.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

Review 9.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

10.  A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

Authors:  David J Lapinsky; Shaili Aggarwal; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Roxanne A Vaughan
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.